CRISPR/Cas9 technology using gRNA 5' CATTGCCACGAAGCTGGC-GG 3' introduced a C to T change at position 1427 resulting in an alanine to valine substitution at amino acid 476 (A476V). This corresponds to the human A478V mutation associated with Cantu Syndrome.